Symbicort Turbuhaler 30/60 Specific Clinical Experience Investigation
Completed
- Conditions
- Bronchial Asthma
- Registration Number
- NCT01232335
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to confirm the safety profile for long term treatment and maximize doses and the control status on bronchial asthma in daily clinical usage
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1500
Inclusion Criteria
- Patients treated with Symbicort for the first time possibly at the higher dose due to bronchial asthma
Exclusion Criteria
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of Adverse Events Range of one year
- Secondary Outcome Measures
Name Time Method The level of asthma control under long-term use At the end of one year
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of budesonide and formoterol in Symbicort Turbuhaler for bronchial asthma management?
How does Symbicort Turbuhaler 30/60 compare to standard ICS/LABAs in long-term asthma control and safety?
Which biomarkers correlate with improved asthma control in NCT01232335 Symbicort Turbuhaler long-term study?
What are the long-term adverse events observed in NCT01232335 Symbicort Turbuhaler study and their management strategies?
What are the therapeutic advantages of Symbicort Turbuhaler over newer biologics in moderate-to-severe asthma management?
Trial Locations
- Locations (1)
Research Site
🇯🇵Yamanashi, Japan